Meriva curcumin-phospholipid complex, 2 g/day, as add-on therapy,
does it really help with Improvement of PASI in mild-to-moderate plaque psoriasis?
research showsGrade C with 50 points. Adding Meriva 2 g/day to topical steroids produced a larger 12-week PASI reduction, but only 49 of 63 participants completed, manufacturer support was present, and PASI75 was secondary.
ads claimThe trial does not show that dietary turmeric or generic powder treats psoriasis or replaces topical steroids.
Useful facts when choosing a product
- This verdict applies only to the exact formulation, route, dose, duration, population, endpoint, and comparator shown above.
- Conventional curcumin, turmeric powder, nano or micellar products, phospholipid phytosomes, piperine combinations, swallowed products, and topical oral products are not interchangeable.
- Caution. Twelve weeks cannot exclude long-term hepatic, biliary, or bleeding risks, and soy-lecithin allergy may matter for this formulation.
Chamgap Semantic Classification Code
Permanent code issued
S.meriva-curcumin-phospholipid.oral.psoriasis-pasi.improve.addonSupplements and nutraceuticals > Meriva curcumin-phospholipid complex > Oral > Psoriasis PASI > Improvement claim > Add-on to topical steroids
Issued for a specific commercial phytosomal add-on formulation, not generic curcumin. The code identifies the intervention and claim; it never contains the evidence grade, score, or safety result.
Exact Claim Classification
These independent facets prevent evidence from different forms, routes, populations, effects, and comparators from being mixed.
| Intervention class | S · Supplement or nutraceutical |
|---|---|
| Canonical ingredient or intervention | Meriva curcumin-phospholipid complex |
| Source or part used | Curcuma longa curcuminoids in a soy-lecithin phospholipid carrier |
| Formulation or processing | Commercial phospholipid phytosome, approximately 20% curcuminoids |
| Route | Oral |
| Dose | Meriva 2 g/day |
| Duration | 12 weeks of treatment and follow-up |
| Population | Adults with mild-to-moderate plaque psoriasis, PASI below 10 |
| Effect or condition | PASI improvement |
| Primary endpoint | Change in PASI at 12 weeks |
| Comparator | Topical steroids alone in both groups |
| Duplicate-detection key | meriva-curcumin-phospholipid|phytosome|oral|mild-moderate-plaque-psoriasis|pasi-improvement|12-weeks |
What the research actually shows
Sixty-three adults were assigned to topical steroids plus Meriva or topical steroids alone.
Why this is classified as C (50)
A direct positive PASI result is offset by manufacturer support, 22% attrition, small size, and a surrogate scale, yielding C with 50 points.
Counterpoint. PASI reduction and IL-22 moved coherently, but PASI75 was secondary and long-term relapse is unknown.
Rejudgment record. Independent Codex cross-check — One formulation, one route, one population, one claim, one principal endpoint and comparator
| Endpoint | S | Surrogate marker - laboratory or imaging measures |
| Replication | R1 | Single confirmatory trial |
| Independence | I0 | Evidence comes only from manufacturer studies |
| Effect size | E+ | Meets the clinically important threshold |
| Precision | C0 | The confidence interval leaves room for benefit |
The scoring table and the verdict agree (C).
Cross-check — AI research and Codex final gate
Evidence Table
| Study | Design | Sample | Funding | Endpoint | Result | Weight |
|---|---|---|---|---|---|---|
| Oral Curcumin (Meriva) Is Effective as an Adjuvant Treatment and Is Able to Reduce IL-22 Serum Levels in Patients with Psoriasis Vulgaris | The cited design and its allocation, masking, endpoint, and analysis limitations were independently checked. | 49 | Funding, product support, employee authorship, and declared conflicts were assessed separately. | The principal endpoint is preserved; secondary and mechanistic outcomes remain separate. | The verified numerical result is preserved in the English reader answer and rationale; missing confidence intervals were not invented. | Evidence weight reflects directness, formulation match, endpoint hierarchy, and verified analysis limitations. |
Receipt — 1 References
All 1 cited sources were verified for existence at the original page (as of 2026-09-08).
Final verification and publication gate: Codex · Verification cutoff: 2026-09-08 · Corrections: none
Cite this verdict
[Chamgap] Meriva Curcumin Complex for Psoriasis PASI—Positive as an Add-on, With 49 of 63 Completing — Evidence Grade C·50. 1 cited sources checked. Source: https://chamgap.com/en/verdicts/skin-hair/oral-meriva-adjunct-mild-moderate-plaque-psoriasis-pasi/ · CC BY 4.0CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.
What this document does and does not do
Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.